Probius Combines AI and Spectroscopy to Advance Diagnostics
Access to advanced medical testing remains a challenge in many parts of the world. This is especially true in low-resource and underserved communities.
New technologies could help make testing more accessible. Probius is exploring one such approach by combining artificial intelligence (AI) with advanced spectroscopy.
Probius, a Propel(x) portfolio company, is developing new tools for biomedical analysis and diagnostics. Its Quantum Electrochemical Spectroscopy (QES) platform captures complex information from biological samples.
The company then uses computational methods to analyze this information. This approach could support new applications in healthcare and life sciences.
Combining AI and Spectroscopy
Spectroscopy can capture information from biological samples. However, the data can be complex and difficult to interpret.
Probius combines spectroscopy with computational analysis to address this challenge.
Its QES platform is designed to capture molecular information from biological samples. The platform then converts this information into data that AI and other computational tools can analyze.
The technology began through DARPA-funded research at Stanford University. Probius is now developing the platform for applications in diagnostics, biomedical research, and drug discovery.
Advancing Tuberculosis Screening
Tuberculosis, or TB, remains a major global health challenge. Access to effective screening can also be difficult in underserved communities.
Probius is developing its technology to address this need.
The company received a $1.48 million grant from the Bill & Melinda Gates Foundation to advance tuberculosis screening technology for low-resource and underserved populations.
This support will help Probius continue developing its AI-enabled approach to TB screening.
The goal is to explore new ways to make biological testing more accessible. However, the technology remains under development as the company continues its research.
Reaching 100,000 Units
Probius has also reached an important manufacturing milestone.
The company reported that it has fabricated 100,000 units of its technology.
This milestone marks progress toward larger-scale production. It also provides an important step as Probius continues to develop and expand its platform.
Manufacturing at scale can help technology companies prepare for wider testing and future deployment. For Probius, the milestone supports its efforts to move the QES platform beyond development and toward broader use.
Exploring Healthcare Applications
Probius is exploring several potential applications for its technology.
These include:
- Diagnostics: Developing new ways to analyze biological samples.
- Tuberculosis screening: Supporting screening in low-resource and underserved communities.
- Biomedical research: Generating biological data for research.
- Drug discovery: Exploring how molecular information could support the development of new therapies.
These applications remain areas of ongoing development.
As the company advances its QES platform, it continues to explore how spectroscopy and AI can work together across healthcare and life sciences.
Making Biological Data More Accessible
AI can only provide useful insights when researchers have access to meaningful data.
For this reason, technologies that can generate and analyze biological information could play an important role in future healthcare research.
Probius is working to connect biological sensing with computational analysis. Its QES platform captures complex biological information and creates data that computational models can process.
This approach could support more scalable ways to collect and study biological information.
Connecting Technology With Global Health
Probius’ work on tuberculosis screening highlights the potential global-health applications of its technology.
The Gates Foundation grant supports development for low-resource and underserved populations. At the same time, the company’s 100,000-unit manufacturing milestone shows progress toward scaling its technology.
Together, these developments highlight two important areas of Probius’ work: accessibility and scalability.
The company continues to explore how its technology can support healthcare applications where advanced testing may be difficult to access.
Advancing AI-Powered Diagnostics
Probius is working at the intersection of AI, spectroscopy, and biomedical analysis.
Its QES platform provides the foundation for this work. Meanwhile, its tuberculosis screening program focuses on an important global health need.
The company has also made progress in manufacturing, with 100,000 units fabricated.
As development continues, Probius is exploring how its technology could support diagnostics, biomedical research, and drug discovery.
We’re proud to see the Probius team continue advancing its QES platform and exploring new ways to combine AI and spectroscopy for more accessible biological analysis and diagnostic tools.
Learn more about Probius on Propelx.com.
